Clinical Profile, Immunosuppressive Management and Outcome in Adult Renal Allograft Recipients with COVID-19 Infection
Research Journal of Critical Care Nephrology · 19.10.2026 · 2 (04) · 289-300
DOI: 10.66224/rjccn.2.04.53 ↗Kurz gefasst
Fachartikel in der Zeitschrift Research Journal of Critical Care Nephrology, online erschienen am 19.10.2026. Verfasst von Sonia Mahjabin und 4 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Coronavirus disease 2019 (COVID-19) has placed considerable strain on healthcare systems worldwide with renal allograft recipients (RARs) representing a particularly vulnerable group. Lifelong immunosuppression increases susceptibility to severe infection and complicates clinical management. Data on COVID-19 in RARs from South Asia and other resource-limited settings are limited. This study describes the clinical features, immunosuppressive adjustments, and outcomes of renal allograft recipients with COVID-19.
Methods
We analyzed data from 26 adult RARs with moderateto-severe COVID-19, confirmed by RT-PCR, who were admitted to the Department of Nephrology, Continental Hospital PLC (previous United Hospital Limited) Dhaka, Bangladesh, between December 2020 and June 2025.
Results
The mean age was 59.6 years (range: 34 to 75 years), and 73.1% of patients were male. DM (46.2%), glomerulonephritis (23.1%), and hypertensive nephrosclerosis (19.2%) were the most common primary renal diseases. The most frequent symptoms were cough (96.2%) and fever (88.5%). Immunosuppressive therapy was modified in all patients: antimetabolites were discontinued, corticosteroids were switched to dexamethasone or IV methylprednisolone, and CNIs were withheld in 34.6% or halved in 26.9%. Laboratory results showed elevated inflammatory markers (CRP 96.4 mg/L, ferritin 854.3 ng/mL, D-dimer 2016.3 ng/mL). Chest CT revealed ground-glass opacities in 76.9% (most commonly bilateral peripheral, 35%) and consolidation in 61.5%, with a mean total severity score of 9.6 ± 4.9. Acute kidney injury occurred in 26.9%, among them 23.1%required dialysis and 7.7% remained dialysis-dependent. Mechanical ventilation was needed in 23.1%. Overall mortality was 26.9%, while 65.4% of patients recovered and were discharged.
Conclusion
COVID-19 is associated with significant morbidity and mortality in RARs. Despite most patients recovering, mortality remained significant, highlighting the need for careful immunosuppressive adjustment, aggressive infection control, and close monitoring in this high-risk population.
Zitieren
APA
Mahjabin, S., Islam, N., Rahman, R., Haque, E., & Mobin, M. E. (2026). Clinical Profile, Immunosuppressive Management and Outcome in Adult Renal Allograft Recipients with COVID-19 Infection. Research Journal of Critical Care Nephrology, 2(04), 289-300. https://doi.org/10.66224/rjccn.2.04.53
Vancouver
Mahjabin S, Islam N, Rahman R, Haque E, Mobin ME. Clinical Profile, Immunosuppressive Management and Outcome in Adult Renal Allograft Recipients with COVID-19 Infection. Research Journal of Critical Care Nephrology. 2026;2(04):289-300. doi:10.66224/rjccn.2.04.53
BibTeX
@article{Mahjabin2026,
author = {Mahjabin, Sonia and Islam, Nurul and Rahman, Rezwanur and Haque, Elena and Mobin, Muntasir Ebne},
title = {Clinical Profile, Immunosuppressive Management and Outcome in Adult Renal Allograft Recipients with COVID-19 Infection},
journal = {Research Journal of Critical Care Nephrology},
year = {2026},
volume = {2},
number = {04},
pages = {289--300},
doi = {10.66224/rjccn.2.04.53}
}
EUVIMED